Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tania Jain

Showing results (1-10 of 118) with videos related to

Pageof 12
Sort By:
Cureus|January 30, 2016
Intermittent BRAF Inhibition Can Achieve Prolonged Disease Control in BRAF Mutant MelanomaTania Jain, Alan Bryce
Expert Review of Anticancer Therapy|September 7, 2016
The development, safety and efficacy of pacritinib for the treatment of myelofibrosisTania Jain, Ruben Mesa
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 22, 2016
Bone Disease in Myeloma: The Claws of CRABRafael Fonseca, Tania Jain
Ejhaem|July 18, 2022
CAR-T-OPENIA: Chimeric antigen receptor T-cell therapy-associated cytopeniasAlankrita Taneja, Tania Jain
Hematology. American Society of Hematology. Education Program|December 4, 2018
No free rides: management of toxicities of novel immunotherapies in ALL, including financialTania Jain, Mark R Litzow
Therapeutic Advances in Hematology|February 4, 2020
Management of toxicities associated with novel immunotherapy agents in acute lymphoblastic leukemiaTania Jain, Mark R Litzow
Hematology/Oncology Clinics of North America|March 1, 2021
Accelerated and Blast Phase Myeloproliferative NeoplasmsTania Jain, Raajit K Rampal
Blood Advances|November 29, 2018
No free rides: management of toxicities of novel immunotherapies in ALL, including financialTania Jain, Mark R Litzow
Case Reports in Hematology|September 20, 2019
HHV-8-Associated Lymphoproliferative Disorders and Pathogenesis in an HIV-Positive PatientCarlo Guerrero, Tania Jain, Katalin Kelemen
British Journal of Haematology|May 26, 2021
Graft-versus-host disease risk after chimeric antigen receptor T-cell therapy: the diametric opposition of T cellsKhaled Sanber, Bipin Savani, Tania Jain
Pageof 12

Showing results (1-10 of 118) with videos related to

Sort By:
Pageof 12
Cureus|January 30, 2016
Intermittent BRAF Inhibition Can Achieve Prolonged Disease Control in BRAF Mutant MelanomaTania Jain, Alan Bryce
Expert Review of Anticancer Therapy|September 7, 2016
The development, safety and efficacy of pacritinib for the treatment of myelofibrosisTania Jain, Ruben Mesa
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 22, 2016
Bone Disease in Myeloma: The Claws of CRABRafael Fonseca, Tania Jain
Ejhaem|July 18, 2022
CAR-T-OPENIA: Chimeric antigen receptor T-cell therapy-associated cytopeniasAlankrita Taneja, Tania Jain
Hematology. American Society of Hematology. Education Program|December 4, 2018
No free rides: management of toxicities of novel immunotherapies in ALL, including financialTania Jain, Mark R Litzow
Therapeutic Advances in Hematology|February 4, 2020
Management of toxicities associated with novel immunotherapy agents in acute lymphoblastic leukemiaTania Jain, Mark R Litzow
Hematology/Oncology Clinics of North America|March 1, 2021
Accelerated and Blast Phase Myeloproliferative NeoplasmsTania Jain, Raajit K Rampal
Blood Advances|November 29, 2018
No free rides: management of toxicities of novel immunotherapies in ALL, including financialTania Jain, Mark R Litzow
Case Reports in Hematology|September 20, 2019
HHV-8-Associated Lymphoproliferative Disorders and Pathogenesis in an HIV-Positive PatientCarlo Guerrero, Tania Jain, Katalin Kelemen
British Journal of Haematology|May 26, 2021
Graft-versus-host disease risk after chimeric antigen receptor T-cell therapy: the diametric opposition of T cellsKhaled Sanber, Bipin Savani, Tania Jain
Pageof 12